This math transform tool runs Price Common Logarithm transformation and companion studies for Protagenic Therapeutics. This view tracks price transformations that reveal shifts in trend structure to support structured performance interpretation without implying advice.
This analysis covers sixty-one data points across the selected time horizon. Protagenic Therapeutics Price Common Logarithm is logarithm with base 10 applied on the entire pricing series.
Most technical analysis of Protagenic Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Protagenic from various momentum indicators to cycle indicators. When you analyze Protagenic charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. Liquidity and trading activity can influence how quickly new information is reflected in Protagenic Therapeutics's price. Lower trading activity may introduce occasional variability in execution conditions. Protagenic Therapeutics has a market cap of 944.67 K, P/E of 9.43, ROE of -5.13%.
Methodology
Unless otherwise specified, financial data for Protagenic Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Protagenic (USA Stocks:PTIX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Protagenic Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Protagenic Therapeutics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Tracking Protagenic Therapeutics inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. The stronger process keeps portfolio transparency high without forcing constant manual review of every holding.
Generate Optimal Portfolios
Align your risk and return expectations
Risk tolerance and time horizon inputs allow Macroaxis optimization to estimate acceptable risk levels. The output provides a structured risk context for return targets.
A comprehensive view of Protagenic Therapeutics starts with financial statements and ratio context. Ratio analysis helps investors evaluate Protagenic Therapeutics Stock operating efficiency and financial trajectory. Highlighted below are reports that provide context for Protagenic Therapeutics Stock:
Protagenic Therapeutics has a market cap of 944.67 K, ROE of -5.13%. Your Equity Center can help frame allocation decisions. This includes a position in Protagenic Therapeutics in the portfolio view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
New to investing in Protagenic Stock? Start with our How to Invest in Protagenic Stock guide for a step-by-step overview.With Protagenic Therapeutics showing P/E 9.43 and ROE -5.13%, investors get more value when this analysis is combined with the diversification and construction tools below. That discounted valuation invites deeper analysis through the value and risk tools below. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Earnings Share
-13.13
Return On Assets
-1.90
Return On Equity
-5.13
Investors evaluate Protagenic Therapeutics using market value and book value, each describing different facets of the business. Protagenic Therapeutics' market capitalization is 944.67 K. The 3.35 P/B ratio shows Protagenic Therapeutics carries a substantial premium over its balance-sheet equity. Enterprise value stands at 2.22 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
It is useful to distinguish Protagenic Therapeutics' value from its trading price, which are computed with different methods. For Protagenic Therapeutics, key inputs include a P/E ratio of 9.43, a P/B ratio of 3.35, and ROE of -5.13%. In practice, Protagenic Therapeutics price is set by the continuous auction process on its listing exchange.